Zhejiang Jingxin Pharmaceutical Co., Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE000001K73
CNY
19.08
5.21 (37.56%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationAnnual Results
Results Snapshot
Figures in Million
Consolidate Annual Results
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
Dec'19
Dec'18
Net Sales
4,108.68
3,952.09
3,741.79
3,436.94
3,226.27
3,605.88
2,903.49
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
4,108.68
3,952.09
3,741.79
3,436.94
3,226.27
3,605.88
2,903.49
Raw Material Cost
2,162.09
2,048.32
1,857.10
1,629.55
1,354.75
1,329.73
1,082.38
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
9.73
9.88
7.75
6.71
7.68
12.40
6.75
Selling and Distribution Expenses
883.34
959.15
933.22
948.07
1,139.65
1,560.24
1,246.34
Other Expenses
34.39
36.19
31.91
28.26
20.82
21.67
21.39
Total Expenditure (Excl Depreciation)
3,399.08
3,379.26
3,117.20
2,866.98
2,710.28
3,119.08
2,549.42
Operating Profit (PBDIT) excl Other Income
709.5999999999999
572.8
624.6
570
516
486.8
354.09999999999997
Other Income
182.21
118.96
132.97
143.33
126.50
131.21
73.75
Operating Profit (PBDIT)
1,205.33
919.61
951.29
893.92
795.91
726.37
523.67
Interest
9.73
9.88
7.75
6.71
7.68
12.40
6.75
Exceptional Items
-40.19
25.82
10.89
-0.90
131.41
-0.10
-0.26
Gross Profit (PBDT)
1,946.59
1,903.77
1,884.69
1,807.39
1,871.52
2,276.15
1,821.12
Depreciation
310.77
221.47
199.95
182.53
154.42
115.31
98.23
Profit Before Tax
844.64
714.08
754.48
703.79
765.21
598.56
418.42
Tax
124.85
84.62
82.49
81.57
105.65
81.47
43.95
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
711.96
618.90
662.25
612.54
653.07
520.40
369.28
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
711.96
618.90
662.25
612.54
653.07
520.40
369.28
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
7.16
4.52
5.57
5.42
0.26
1.55
1.33
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
719.13
623.42
667.82
617.96
653.33
521.95
370.62
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
1.0
1.0
1.0
1.0
1.0
1.0
1.0
Reserves
5,969.51
5,512.37
5,146.12
4,861.54
3,917.60
3,696.08
3,586.57
Earnings per share (EPS)
0.83
0.72
0.77
0.75
0.83
0.64
0.43
Diluted Earnings per share
0.83
0.72
0.77
0.75
0.83
0.64
0.43
Operating Profit Margin (Excl OI)
17.34%
14.66%
16.53%
16.53%
15.96%
13.31%
12.11%
Gross Profit Margin
28.12%
23.67%
25.51%
25.79%
28.5%
19.8%
17.79%
PAT Margin
17.33%
15.66%
17.7%
17.82%
20.24%
14.43%
12.72%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Annual Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Dec 2024 is 3.96% vs 5.62% in Dec 2023

stock-summary

Consolidate Net Profit

YoY Growth in year ended Dec 2024 is 15.35% vs -6.65% in Dec 2023

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Dec 2024 is 27.78% vs -2.15% in Dec 2023

stock-summary

Interest

YoY Growth in year ended Dec 2024 is -2.02% vs 28.57% in Dec 2023

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in year ended Dec 2024 has improved from Dec 2023

Compare Annual Results Of Zhejiang Jingxin Pharmaceutical Co., Ltd. With
Markets Mojo
Figures in Million
Consolidate Annual Results
Markets Mojo
Markets Mojo
Change(CNY)
Change(%)
Net Sales
4,108.68
0
4,108.68
Other Operating Income
0.00
0.00
0.00
Total Operating income
4,108.68
0
4,108.68
Raw Material Cost
2,162.09
0
2,162.09
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
9.73
0
9.73
Selling and Distribution Expenses
883.34
0
883.34
Other Expenses
34.39
0.00
34.39
Total Expenditure (Excl Depreciation)
3,399.08
0
3,399.08
Operating Profit (PBDIT) excl Other Income
709.60
0.00
709.60
Other Income
182.21
0
182.21
Operating Profit (PBDIT)
1,205.33
0
1,205.33
Interest
9.73
0
9.73
Exceptional Items
-40.19
0
-40.19
Gross Profit (PBDT)
1,946.59
0
1,946.59
Depreciation
310.77
0
310.77
Profit Before Tax
844.64
0
844.64
Tax
124.85
0
124.85
Provisions and contingencies
0
0
0.00
Profit After Tax
711.96
0
711.96
Extraordinary Items
0.00
0
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
711.96
0
711.96
Share in Profit of Associates
0
0
0.00
Minority Interest
7.16
0
7.16
Other related items
0.00
0.00
0.00
Consolidated Net Profit
719.13
0
719.13
Equity Capital
0
0
0.00
Face Value
1.00
0
0.00
Reserves
5,969.51
0
5,969.51
Earnings per share (EPS)
0.83
0
0.83
Diluted Earnings per share
0.83
0
0.83
Operating Profit Margin (Excl OI)
17.34%
0%
0.00
17.34%
Gross Profit Margin
28.12%
0%
0.00
28.12%
PAT Margin
17.33%
0%
0.00
17.33%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Annual - Net Sales
Net Sales 410.87 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is 3.96% vs 5.62% in Dec 2023

Annual - Consolidate Net Profit
Consolidate Net Profit 71.91 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is 15.35% vs -6.65% in Dec 2023

Annual - Operating Profit (PBDIT)
Operating Profit (PBDIT) 102.31 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is 27.78% vs -2.15% in Dec 2023

Annual - Interest
Interest 0.97 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is -2.02% vs 28.57% in Dec 2023

Annual - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 17.34%
in Dec 2024

Figures in %
stock-summary

YoY Growth in year ended Dec 2024 has improved from Dec 2023